Literature DB >> 22621971

High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.

T Yang1, J-H Lu, J Zhai, C Lin, G-S Yang, R-H Zhao, F Shen, M-C Wu.   

Abstract

PURPOSE: The aim of this prospective cohort study was to investigate the impact of preoperative hepatitis B viral load, as well as postoperative antiviral therapy, on the risk of long-term survival after curative resection of hepatitis B virus-related hepatocellular carcinoma (HCC).
METHODS: A prospective cohort of hepatitis B virus-related HCC patients undergoing curative resection from 2002 to 2008 was studied. According to preoperative viral load (using 10,000 copies/mL of hepatitis B virus DNA level as cut-off value), two groups were compared. Prognostic factors for overall survival and recurrence-free survival were evaluated. Additionally, subgroup analysis was conducted in patients with high viral load to investigate prediction of postoperative antiviral therapy on the long-term prognosis.
RESULTS: With a median follow-up of 49.1 months, patients with high viral load had lower median overall survival (78.3 months vs. 111.4 months, P<0.001) and RFS (44.6 months vs. 94.8 months, P<0.001) compared with those with low viral load. Multivariate analysis revealed that preoperative high viral load was an independent risk factor affecting both overall survival and recurrence-free survival (both P<0.001). The subgroup analysis revealed that postoperative antiviral therapy independently improved recurrence-free survival for patients with high viral load (P=0.001).
CONCLUSIONS: Hepatitis B virus-related HCC patients with preoperative high viral load led to poorer overall and recurrence-free survival than those with low viral load after curative resection. To prevent postoperative recurrence, antiviral therapy should be initiated in those patients with hepatitis B virus DNA ≥ 10,000 copies/ml.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621971     DOI: 10.1016/j.ejso.2012.04.010

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  32 in total

Review 1.  Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.

Authors:  Xiao-Jun Lin; Xiang-Ming Lao; Ming Shi; Sheng-Ping Li
Journal:  Dig Dis Sci       Date:  2016-04-22       Impact factor: 3.199

Review 2.  Hepatectomy for hepatocellular carcinoma in the era of liver transplantation.

Authors:  Wen-Ping Lu; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

Review 3.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

4.  Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zhi-Wei Jian; Xi-Wen Wu; Zhen-Xin Chen; Jun-Cheng Wang; Jing-Yuan Peng; Xiang-Ming Lao
Journal:  Dig Dis Sci       Date:  2019-02-28       Impact factor: 3.199

Review 5.  Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis.

Authors:  Yanming Zhou; Zhansai Zhang; Yanfang Zhao; Lupeng Wu; Bin Li
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 6.  Hepatitis B viral load affects prognosis of hepatocellular carcinoma.

Authors:  Su Jong Yu; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

7.  Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zheng Li; Zhengqing Lei; Yong Xia; Jun Li; Kui Wang; Han Zhang; Xuying Wan; Tian Yang; Weiping Zhou; Mengchao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen
Journal:  JAMA Surg       Date:  2018-10-17       Impact factor: 14.766

8.  Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis.

Authors:  Guangcong Zhang; Xiangnan Yu; Peng Liu; Xiaoxi Huang; Xuemei Jiang
Journal:  Dig Dis Sci       Date:  2018-08-23       Impact factor: 3.199

9.  The role of liver transplantation or resection for patients with early hepatocellular carcinoma.

Authors:  Kuan-Chun Hsueh; Ting-Ying Lee; Chew-Teng Kor; Tsung-Ming Chen; Tzu-Ming Chang; Shun-Fa Yang; Chung-Bao Hsieh
Journal:  Tumour Biol       Date:  2015-10-22

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.